Literature DB >> 12200906

Cardiovascular changes in children with mucopolysaccharide disorders.

U R Mohan1, A A Hay, M A Cleary, J E Wraith, R G Patel.   

Abstract

UNLABELLED: The aims of this study were to evaluate cardiac involvement, assess risk factors and mortality, and define the outcome of cardiac abnormalities with age in the different types of mucopolysaccharidoses (MPS). The echocardiograms of 99 patients with MPS, aged 1-24 y (median age 10.3 y) were reviewed between 1978 and 2000. Mitral regurgitation (MR) was detected in 29 patients (29%). MR was more frequent in types IH [n = 11 (38%)], II [n = 10 (24%)] and III [n = 4 (20%)]. Sixteen patients (16%) developed aortic regurgitation (AR), seen mostly in types II [n = 9 (56%)] and IV [n = 4 (24%)]. AR and/or MR was detected in 37 patients and 8 had both abnormalities of borderline significance (odds ratio 2.95, 95% confidence interval 1.0-8.85, p = 0.05). Of 99 patients, 47 had a normal study on their first echocardiogram, whereas only 7 had a normal study on subsequent echocardiograms. Fifty-four (54%) had a single echocardiogram. Of these, 27 (50%) were abnormal and 27 normal. Forty-five patients had more than one echocardiogram, of which 25 (56%) were abnormal and 20 normal. In 13/20 (65%) a cardiac abnormality developed on a subsequent echocardiogram which was statistically significant (p = 0.002). Overall mitral and aortic valve abnormalities showed a positive association with age. Univariate analysis of risk factors showed that increasing age, MPS I and ejection fraction were significant risk factors for death. However, left ventricular hypertrophy, mitral valve abnormalities and type II MPS were not significant risk factors for death, with borderline significance for aortic valve abnormalities.
CONCLUSION: This study demonstrates the evaluation of ventricular function, which is a significant risk factor for death, along with increasing age and MPS I, and outlines the borderline significance of aortic valve abnormalities, which has not been mentioned in previous studies. It also shows that mitral valve lesions, commonly seen in MPS, were not a significant risk factor for death. The results emphasize the importance of performing serial echocardiograms in patients with MPS to assess ventricular function and the progression of cardiac abnormalities with age.

Entities:  

Mesh:

Year:  2002        PMID: 12200906     DOI: 10.1080/08035250213211

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  25 in total

1.  Natural history of echocardiographic abnormalities in mucopolysaccharidosis III.

Authors:  Carolyn M Wilhelm; Kristen V Truxal; Kim L McBride; John P Kovalchin; Kevin M Flanigan
Journal:  Mol Genet Metab       Date:  2018-04-27       Impact factor: 4.797

Review 2.  The heart in Anderson-Fabry disease and other lysosomal storage disorders.

Authors:  Ales Linhart; Perry M Elliott
Journal:  Heart       Date:  2007-04       Impact factor: 5.994

3.  Sleep-related breathing in children with mucopolysaccharidosis.

Authors:  A Nashed; S Al-Saleh; J Gibbons; I MacLusky; J MacFarlane; A Riekstins; J Clarke; I Narang
Journal:  J Inherit Metab Dis       Date:  2009-06-28       Impact factor: 4.982

4.  Cardiac Ultrasound Findings in Infants with Severe (Hurler Phenotype) Untreated Mucopolysaccharidosis (MPS) Type I.

Authors:  L Schroeder; P Orchard; C B Whitley; J M Berry; J Tolar; W Miller; E A Braunlin
Journal:  JIMD Rep       Date:  2013-02-12

Review 5.  Genetics and metabolic cardiomyopathies.

Authors:  E C Wicks; P M Elliott
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

6.  Cardiac manifestations in the mouse model of mucopolysaccharidosis I.

Authors:  Maria C Jordan; Yi Zheng; Sergey Ryazantsev; Nora Rozengurt; Kenneth P Roos; Elizabeth F Neufeld
Journal:  Mol Genet Metab       Date:  2005-06-24       Impact factor: 4.797

Review 7.  Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders.

Authors:  E I Parker; M Xing; A Moreno-De-Luca; E Harmouche; M R Terk
Journal:  Br J Radiol       Date:  2013-11-14       Impact factor: 3.039

8.  Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy.

Authors:  Christoph Kampmann; Christina Lampe; Catharina Whybra-Trümpler; Christiane M Wiethoff; Eugen Mengel; Laila Arash; Michael Beck; Elke Miebach
Journal:  J Inherit Metab Dis       Date:  2013-09-24       Impact factor: 4.982

9.  Review of the use of idursulfase in the treatment of mucopolysaccharidosis II.

Authors:  T Andrew Burrow; Nancy D Leslie
Journal:  Biologics       Date:  2008-06

10.  Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I.

Authors:  O I I Soliman; R G M Timmermans; A Nemes; W B Vletter; J H P Wilson; F J ten Cate; M L Geleijnse
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.